CN106511915A - Applications of compound traditional Chinese medicinal composition in preparing medicines for inhibiting skin melanoma lung metastasis - Google Patents
Applications of compound traditional Chinese medicinal composition in preparing medicines for inhibiting skin melanoma lung metastasis Download PDFInfo
- Publication number
- CN106511915A CN106511915A CN201710029836.8A CN201710029836A CN106511915A CN 106511915 A CN106511915 A CN 106511915A CN 201710029836 A CN201710029836 A CN 201710029836A CN 106511915 A CN106511915 A CN 106511915A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- rhizoma
- chinese medicine
- compound traditional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 99
- 150000001875 compounds Chemical class 0.000 title claims abstract description 50
- 229940079593 drug Drugs 0.000 title claims abstract description 25
- 201000001441 melanoma Diseases 0.000 title claims abstract description 21
- 239000000203 mixture Substances 0.000 title claims abstract description 10
- 208000030381 cutaneous melanoma Diseases 0.000 title claims abstract description 8
- 201000003708 skin melanoma Diseases 0.000 title claims abstract description 8
- 210000004072 lung Anatomy 0.000 title abstract description 14
- 206010027476 Metastases Diseases 0.000 title abstract description 9
- 230000009401 metastasis Effects 0.000 title abstract description 9
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 239000009636 Huang Qi Substances 0.000 claims abstract description 13
- 239000002131 composite material Substances 0.000 claims description 25
- 206010027458 Metastases to lung Diseases 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 241000756943 Codonopsis Species 0.000 claims description 12
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 12
- 239000012467 final product Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 238000005728 strengthening Methods 0.000 claims description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 241000497005 Ixophorus unisetus Species 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 241000132012 Atractylodes Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241001619444 Wolfiporia cocos Species 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 210000000952 spleen Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002386 leaching Methods 0.000 description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011354 first-line chemotherapy Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- -1 tabletting Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses applications of a compound traditional Chinese medicinal composition in preparing medicines for inhibiting skin melanoma lung metastasis. The compound traditional Chinese medicinal composition is prepared from the following components in parts by weight: 15-30 parts of radix astragali preparata, 15-30 parts of stir-baked radix codonops, 10-20 parts of stir-baked white atractylodes rhizome, 15-30 parts of poria cocos, 15-30 parts of rhizoma dioscoreae, 5-10 parts of radix glycyrrhizae preparata, 10-20 parts of smoked plum preparata, 10-20 parts of rhizoma sparganii, 10-20 parts of rhizoma curcumae, 15-30 parts of herba agrimoniae, and 15-30 parts of herba patriniae. The compound traditional Chinese medicinal composition provided by the invention can obviously inhibit the skin melanoma lung metastasis under the condition that the body immunity is not reduced, and meanwhile, the medicine is low in preparation cost, and easy to popularize and apply.
Description
Technical field
The present invention relates to traditional Chinese medicine technology, and in particular to a kind of compound traditional Chinese medicine composite is suppressing cutaneous melanoma Lung metastases
Application in medicine.
Background technology
Melanoma is the topmost tumor type of department of dermatologry, and which originates from the melanocyte at epidermal-dermal junction,
The position such as mucosa or ocular choroid can also be derived from.This kind of tumor is relatively rare but grade malignancy highest is a kind of, in institute
In You Fei developed countries, its sickness rate is about 0.1/10 ten thousand people, but its fatality rate accounts for 97%, is easier to metastasis occur, especially
Lung metastases, therefore should attract great attention.
With compatriots' living-pattern preservation, the pollution of environment, the overall incidence of tumor are raised year by year.Tumor patient mesh
It is front except operation is outer, the First-line chemotherapies of many remain the Cocktail treatment based on cytotoxic drug.Chemotherapeutic
Although using Partial tumors cell has been eliminated, for internal normal cell also has certain lethal effect.Clinically patient
Using the situation that hypoimmunity occurs after chemotherapeutic, zoopery shows the experiment mice after 5-fluorouracil intervention, its
Body weight, spleen index, T lymphocyte proliferation activities, CD4/CD8 ratios are substantially reduced, leukopenia, atrophy of immune organ, huge
Phagocyte phagocytic function is reduced and NK cytoactives decline.
For the patient of melanoma, how on the basis of its immunity is not lowered, seek to reduce its metastasis
Supplement with the Therapeutic Method for substituting just into the task of top priority, and Chinese medicine shows its unique advantage in this respect.Mesh
Before have substantial amounts of clinical and Basic Experiment Study to show, Chinese medicine has good curative effect in terms for the treatment of malignant tumor, except
Directly kill outside the effect of tumor, Chinese medicine can also be played and indirectly be acted on, you can reaching with by strengthening vital QI to eliminate pathogenic factors improves disease
Shape, improves the quality of living, and reduces transfer and extends the purpose of life cycle.
The content of the invention
The technical problem to be solved is to provide a kind of compound traditional Chinese medicine composite and is suppressing cutaneous melanoma lung
Application in diversion medicaments.
To solve above-mentioned technical problem, the technical solution used in the present invention is as follows：
A kind of application of compound traditional Chinese medicine composite in cutaneous melanoma Lung metastases medicine is suppressed,
Wherein, described compound traditional Chinese medicine composite includes the component of following parts by weight：15～30 parts of Radix Astragali Preparata, Radix Codonopsis (parched)
15～30 parts, 10～20 parts of Rhizoma Atractylodis Macrocephalae (parched), 15～30 parts of Poria, 15～30 parts of Rhizoma Dioscoreae, 5～10 parts of Radix Glycyrrhizae Preparata process Fructus Mume 10～20
Part, 10～20 parts of Rhizoma Sparganii, 10～20 parts of Rhizoma Curcumae, 15～30 parts of Herba Agrimoniae, 15～30 parts of Herba Patriniae.
Wherein, described compound traditional Chinese medicine composite preferably includes the component of following parts by weight：
15～20 parts of Radix Astragali Preparata, 15～20 parts of Radix Codonopsis (parched), 10～15 parts of Rhizoma Atractylodis Macrocephalae (parched), 15～20 parts of Poria, Rhizoma Dioscoreae 15～30
Part, 5～10 parts of Radix Glycyrrhizae Preparata processs 10～15 parts of Fructus Mume, 10～15 parts of Rhizoma Sparganii, 10～15 parts of Rhizoma Curcumae, 20～30 parts of Herba Agrimoniae, Herba Patriniae
20～30 parts of grass.
Wherein, described compound traditional Chinese medicine composite, its dosage form are decoction, syrup, mixture, granule, tablet or capsule
Agent.
Wherein, described compound traditional Chinese medicine composite is prepared as follows obtaining：By the Chinese crude drug Radix Astragali Preparata of formula ratio, fry
Radix Codonopsis, Rhizoma Atractylodis Macrocephalae (parched), Poria, Rhizoma Dioscoreae, Radix Glycyrrhizae Preparata, process Fructus Mume, Rhizoma Sparganii, Rhizoma Curcumae, Herba Agrimoniae and Herba Patriniae and add water to cook and obtain final product.
Wherein, decoct every time, the weight of the water of addition is 5～20 times of Chinese crude drug gross weight；The number of times of decoction is 1～3
Secondary, each decocting time is 1～3 hour.
The preparation method of above-mentioned compound traditional Chinese medicine composite, after can also adding water to cook, decocting liquid concentration is obtained final product.
Wherein, described concentration, method one is：Decocting liquid is concentrated into into 60 DEG C of relative densities 1.05～1.15.
Wherein, described concentration, method two is：Decocting liquid is concentrated into into 60 DEG C of relative densities 1.05～1.15, then plus ethanol
Extracted up to 60～90% to alcohol content, after solid-liquid separation, taken supernatant, ethanol in supernatant is reclaimed to being concentrated to the greatest extent
Liquid.
The preparation method of above-mentioned compound medicine, adds or is added without sucrose in concentrated solution, sterilizing make syrup or
Decoction；Or, dextrin, steviosin are added in concentrated solution, tablet, capsule or granule are made.
Wherein, described compound traditional Chinese medicine composite is by suppressing melanoma Lung metastases so as to improve the prognosis of disease.
Wherein, described compound traditional Chinese medicine composite can not lower immune cell number while therapeutic effect is reached
Amount.
Compound composite medicament provided by the present invention, the sweet temperature of Radix Astragali Preparata in side, arrogates to oneself air making-up and spleen enlivening, ascending up spleen-Qi and Yang；Radix Codonopsis (parched)
Gan Ping, arrogates to oneself gas, the supplementing QI for promoting the production of body fluid of tonifying the spleen and stomach, and two medicines are shared, and the work(of QI invigorating spleen reinforcing writes, and is monarch drug altogether.Rhizoma Atractylodis Macrocephalae (parched) air making-up and spleen enlivening is dry
Wet, Poria invigorating spleen for diuresis eliminating dampness by diuresis, Rhizoma Dioscoreae QI invigorating spleen reinforcing yin nourishing, three medicines are associated with, dehumidify activating the spleen effect it is evident, temper is filled, have removing dampness it
Power, turbid damp are gone, and increase the work(of spleen invigorating, are ministerial drug altogether, play the work(of replenishing QI to invigorate the spleen eliminating dampness by diuresis.Rhizoma Sparganii, Rhizoma Curcumae, bitter in the mouth are violent, arrogate to oneself the heavily fortified point that disappears
Open the stasis of blood, with it in tonic, both can disappear blood stasis slow, and borrow the power of its circulation, row tonic it is stagnant；The pungent scattered row of Herba Patriniae is stagnant, arrogates to oneself
Eliminating carbuncle evacuation of pus, blood stasis removing and clots absorbing；Herba Agrimoniae puckery is restrained, and arrogates to oneself astringing to arrest bleeding, removing toxic substances dysentery relieving；Process Fructus Mume sour in the mouth and puckery, arrogate to oneself astringing intestine to stop diarrhea and stop
Rush down, pain relieving of promoting the production of body fluid, the effect of five medicines detoxify for adjuvant drug row removing blood stasis, yin fluid astringing altogether.Radix Glycyrrhizae Preparata is sweet to put down to make medicine, invigorating the spleen and replenishing QI,
Heat-clearing and toxic substances removing, coordinating the actions of various ingredients in a prescription.Therefore all medicines share, take its righting QI invigorating, removing blood stasis, the effect of yin fluid astringing detoxifies.
Embodiments in accordance with the present invention, for C57BL/6 mices are used in experiment, can lower black using this compound composite medicament
The Lung metastases degree of melanoma model mice, meets the expection of the traditional Chinese medical science " strengthening vital QI to eliminate pathogenic factors ".
Beneficial effect：Compared with prior art, compound composite medicament of the invention is not with lowering immunity of organisms
In the case of, significantly lower the curative effect of the Lung metastases degree of melanoma, while the making of the medicine is cheap, it is easy to which promoting should
With.
Description of the drawings
Fig. 1：Lung metastases situation after melanoma tumor model mice Chinese medicine intervention compares.
Upper row：The lung of negative control group mice；Lower row：The lung of Chinese medicine compound group mice.In figure, black is to be transferred to lung
Melanoma, white are lung tissue.It can be seen that the lung of matched group almost all black, and the lung of Chinese medicine group still has white to deposit
.
Specific embodiment
With reference to specific embodiment, the present invention is described further.According to following embodiments, can be more preferably geographical
The solution present invention.However, as it will be easily appreciated by one skilled in the art that the content described in embodiment is merely to illustrate the present invention,
And should not also without limitation on the present invention described in detail in claims.
Embodiment 1
A kind of compound composite medicament for lowering melanoma Lung metastases, is grouped into by each group of following parts by weight：
15 parts of Radix Astragali Preparata, 15 parts of Radix Codonopsis (parched), 10 parts of Rhizoma Atractylodis Macrocephalae (parched), 15 parts of Poria, 15 parts of Rhizoma Dioscoreae, 5 parts of Radix Glycyrrhizae Preparata process Fructus Mume 10
Part, 10 parts of Rhizoma Sparganii, 10 parts of Rhizoma Curcumae, 30 parts of Herba Agrimoniae, 30 parts of Herba Patriniae, totally 11 taste medicine.
In prescription ratio, the 11 taste prepared slices of Chinese crude drugs of the above, plus the water of 10 times of amounts of crude drug gross weight are weighed, are decocted and is extracted 3 times,
1 hour every time.Collecting decoction, as decoction.
The decoction of gained is concentrated into relative density 1.10 (60 DEG C of surveys), plus ethanol stands 12 hours to alcohol content up to 60%
More than.Leaching supernatant, reclaims ethanol to the greatest extent, and is concentrated into relative density about 1.10 (60 DEG C of surveys).Simple syrup is added, and plus is steamed
To the suitable decoction pieces 1g of every mL, filtration, subpackage, sterilizing obtain final product compound medicine syrup to distilled water.
Embodiment 2
A kind of compound composite medicament for lowering melanoma Lung metastases, is grouped into by each group of following parts by weight：
15 parts of Radix Astragali Preparata, 30 parts of Radix Codonopsis (parched), 10 parts of Rhizoma Atractylodis Macrocephalae (parched), 20 parts of Poria, 15 parts of Rhizoma Dioscoreae, 5 parts of Radix Glycyrrhizae Preparata process Fructus Mume 10
Part, 15 parts of Rhizoma Sparganii, 15 parts of Rhizoma Curcumae, 30 parts of Herba Agrimoniae, 30 parts of Herba Patriniae, totally 11 taste medicine.
In prescription ratio, the 11 taste prepared slices of Chinese crude drugs of the above, plus the water of 20 times of amounts of crude drug gross weight are weighed, are decocted and is extracted 3 times,
1 hour every time.Collecting decoction, is concentrated into relative density 1.08 (60 DEG C of surveys), plus ethanol stands 24 hours to alcohol content up to 60%
More than, leaching supernatant reclaims ethanol to the greatest extent, and is concentrated into relative density about 1.08 (60 DEG C of surveys).Plus distilled water is to every mL phases
As decoction pieces 1g, mix, filter, subpackage, sterilizing obtains final product compound medicine mixture.
Embodiment 3
A kind of compound composite medicament for lowering melanoma Lung metastases, is grouped into by each group of following parts by weight：
20 parts of Radix Astragali Preparata, 20 parts of Radix Codonopsis (parched), 15 parts of Rhizoma Atractylodis Macrocephalae (parched), 15 parts of Poria, 15 parts of Rhizoma Dioscoreae, 10 parts of Radix Glycyrrhizae Preparata process Fructus Mume
15 parts, 10 parts of Rhizoma Sparganii, 10 parts of Rhizoma Curcumae, 15 parts of Herba Agrimoniae, 15 parts of Herba Patriniae, totally 11 taste medicine.
In prescription ratio, the 11 taste prepared slices of Chinese crude drugs of the above, plus the water of 5 times of amounts of crude drug gross weight are weighed, are decocted and is extracted 3 times,
1 hour every time.Collecting decoction, is concentrated into relative density 1.10 (60 DEG C of surveys), plus ethanol stands 24 hours to alcohol content up to 60%
More than, leaching supernatant reclaims ethanol to the greatest extent, and is concentrated into relative density about 1.33 (60 DEG C of surveys).Add appropriate dextrin, Flos Chrysanthemi
Glycosides, granulation are dried, and granulate, subpackage obtain final product compound medicine granule.
Embodiment 4
A kind of compound composite medicament for lowering melanoma Lung metastases, is grouped into by each group of following parts by weight：
15 parts of Radix Astragali Preparata, 15 parts of Radix Codonopsis (parched), 10 parts of Rhizoma Atractylodis Macrocephalae (parched), 15 parts of Poria, 15 parts of Rhizoma Dioscoreae, 5 parts of Radix Glycyrrhizae Preparata process Fructus Mume 10
Part, 10 parts of Rhizoma Sparganii, 10 parts of Rhizoma Curcumae, 20 parts of Herba Agrimoniae, 20 parts of Herba Patriniae, totally 11 taste medicine.
In prescription ratio, the 11 taste prepared slices of Chinese crude drugs of the above, plus the water of 10 times of amounts of crude drug gross weight are weighed, are decocted and is extracted 3 times,
1 hour every time.Collecting decoction, is concentrated into relative density 1.09 (60 DEG C of surveys), plus ethanol stands 24 hours to alcohol content up to 60%
More than, leaching supernatant reclaims ethanol to the greatest extent, and is concentrated into relative density about 1.35 (60 DEG C of surveys).Add appropriate amount of starch, system
Grain, is dried, and granulate, tabletting, coating, subpackage obtain final product compound medicine tablet.
Embodiment 5
A kind of compound composite medicament for lowering melanoma Lung metastases, is grouped into by each group of following parts by weight：
15 parts of Radix Astragali Preparata, 15 parts of Radix Codonopsis (parched), 10 parts of Rhizoma Atractylodis Macrocephalae (parched), 15 parts of Poria, 15 parts of Rhizoma Dioscoreae, 5 parts of Radix Glycyrrhizae Preparata process Fructus Mume 10
Part, 10 parts of Rhizoma Sparganii, 10 parts of Rhizoma Curcumae, 30 parts of Herba Agrimoniae, 30 parts of Herba Patriniae, totally 11 taste medicine.
In prescription ratio, the 11 taste prepared slices of Chinese crude drugs of the above, plus the water of 10 times of amounts of crude drug gross weight are weighed, are decocted and is extracted 2 times,
1 hour every time.Collecting decoction, is concentrated into relative density 1.12 (60 DEG C of surveys), plus ethanol stands 24 hours to alcohol content up to 60%
More than, leaching supernatant reclaims ethanol to the greatest extent, and is concentrated into relative density about 1.32 (60 DEG C of surveys).Add appropriate amount of starch, system
Grain, is dried, and granulate is encapsulated, and subpackage obtains final product compound medicine capsule.
Chinese medicine compound lowers the experimentation of melanoma Lung metastases：The compound medicine that optionally prepared by above-described embodiment 1-5
Prescription make decoction, carry out the animal experiment of traditional Chinese compound medicine.
Embodiment 6
By taking 1 prescription of typical embodiment as an example, illustrate, other embodiment effect is quite, specific as follows：
Laboratory animal：SPF levels C57BL/6 mice 16, male and female half and half, 15～19g of body weight, purchased from the western pul in Shanghai-must
Triumphant laboratory animal company limited, quality certification number：SCXK (Shanghai) 2013-0016.
Experimental agents：The decoction of 1 prescription of embodiment is prepared, is concentrated into equivalent to crude drug concentration 6g/mL, this is compound mediciness
Thing.
Laboratory animal is grouped：16 mices are randomly divided into into negative control group (physiological saline group) 8 and Chinese medicine compound is controlled
Treatment group 8.Per only tail vein injection 3*105Individual B16F10 mouse melanin tumor cells, the injection same day start each group animal
Corresponding pharmaceutical intervention is given.
Medication：Negative control group gavages normal saline 0.2mL/20g body weight daily, and compound of Chinese medicine group is filled daily
Take traditional Chinese medicine compound recipe (embodiment 1) 0.2mL/20g body weight, and one time a day for the above, continuous 24 days.2 hours after last dose, neck is taken off
Vertebra is put to death animal, weighs, draws materials, and concrete medicine composition and administering mode are shown in Table 1.
1 medicine of table is constituted and administering mode
Experimental result：
1) ordinary circumstance：After administration situations such as daily observation mice spirit, activity, diet, urine, feces, do not find
Abnormal, eye, ear, nose, mouth are showed no secretions.After modeling, 16 mices survive, but interior during the experiment of 24 days, two groups
Mice is dead 3, therefore survival rate is 67.5%, and Chinese medicine group is suitable with negative group.
2) the change situation of the body weight and spleen index of each group mice, in treatment end, without substantially between two groups of Mouse Weight
Difference, Chinese medicine group spleen weight are larger, but the equal ＞ 0.05 of p value, specifically compare and are shown in Table 2.
Situation contrast (n=5) during 2 each group mice treatment end of table
| Group | Body weight (g) | Spleen weight (g) | Spleen index |
| Negative control group (normal saline) | 16.26±0.82 | 0.069±0.0195 | 0.004±0.0011 |
| Chinese medicine compound group | 17.52±2.04 | 0.092±0.0237 | 0.005±0.0011 |
| P value (with negative group ratio) | 0.253 | 0.137 | 0.209 |
3) impact of the Chinese medicine compound to melanoma Lung metastases：
The contrast (n=5) of Pulmonary metastasis focuses size and quantity during 3 each group mice treatment end of table
| Group | ≤1mm | 1～3mm | ≥3mm |
| Negative control group (normal saline) | 9.0±5.6 | 14.4±5.4 | 14.4±3.8 |
| Chinese medicine compound group | 15.6±3.6 | 7.8±4.3 | 3.8±2.0 |
| P value (with negative group ratio) | 0.063 | 0.067 | 0.001 |
At the end of experiment, in the Pulmonary metastasis focuses of Chinese medicine intervention group, the number of diameter≤1mm is more than negative group, but diameter is 1
The metastasis number of～3mm and >=3mm is Chinese medicine group less than negative group, and especially >=3mm groups, its p value are less than 0.05, have
Statistical significance, points out which reduce the Lung metastases of melanoma.
4) impact of the Chinese medicine compound to mouse immune cell content：
Impact of 4 Chinese herbs group of table to mouse peripheral blood immunocyte content
*：The content of macrophage is with all of lymphocyte as denominator, with the simultaneously positive cells of CD45 and F4/80
Obtain for molecular computing.#：The content of NK cells be with all of lymphocyte as denominator, it is simultaneously positive with CD45 and NK1.1
Cell is obtained for molecular computing.
Impact of 5 Chinese herbs group of table to mouse spleen immunocyte content
*：The content of macrophage is with all of lymphocyte as denominator, with the simultaneously positive cells of CD45 and F4/80
Obtain for molecular computing.#：The content of NK cells be with all of lymphocyte as denominator, it is simultaneously positive with CD45 and NK1.1
Cell is obtained for molecular computing.
At the end of experiment, we have detected the content of various immunocytes in the peripheral blood and spleen of mice, compare Chinese medicine
Their change situation after intervention.Test result indicate that (table 4 and table 5), either T cell, NK cells or macrophage, its
Content is not all decreased obviously (p ＜ 0.05) after medicine in use, illustrates the use of the Chinese medicine, is do not have to the immunity of body
The effect of weakening.
Test result indicate that (Fig. 1), in animal integral experiment, the lung of negative control group almost all black is said
There is tumor cell in bright most lung tissue, and the lung of Chinese medicine compound group animal still has the lung tissue of white.Pass through
Count the number of different size of metastasis, it is seen that Lung metastases after Chinese medicine intervention, can be reduced, illustrate that the herbal mixture is suppressing black
In terms of melanoma Lung metastases, effect is obvious.
More than experiment as can be seen that this Chinese medicine compound can on the basis of all kinds of immunocyte contents of body are not reduced,
Its effect in terms of melanoma Lung metastases are suppressed has been given play to, the effect unique of the Chinese medicine compound has been embodied.
Claims (8)
1. application of a kind of compound traditional Chinese medicine composite in suppression cutaneous melanoma Lung metastases medicine is prepared,
Wherein, described compound traditional Chinese medicine composite includes the component of following parts by weight：15～30 parts of Radix Astragali Preparata, Radix Codonopsis (parched) 15～
30 parts, 10～20 parts of Rhizoma Atractylodis Macrocephalae (parched), 15～30 parts of Poria, 15～30 parts of Rhizoma Dioscoreae, 5～10 parts of Radix Glycyrrhizae Preparata process 10～20 parts of Fructus Mume, and three
10～20 parts of rib, 10～20 parts of Rhizoma Curcumae, 15～30 parts of Herba Agrimoniae, 15～30 parts of Herba Patriniae.
2. application according to claim 1, it is characterised in that described compound traditional Chinese medicine composite includes following parts by weight
Component：
15～20 parts of Radix Astragali Preparata, 15～20 parts of Radix Codonopsis (parched), 10～15 parts of Rhizoma Atractylodis Macrocephalae (parched), 15～20 parts of Poria, 15～30 parts of Rhizoma Dioscoreae are processed
5～10 parts of Radix Glycyrrhizae, processs 10～15 parts of Fructus Mume, 10～15 parts of Rhizoma Sparganii, 10～15 parts of Rhizoma Curcumae, 20～30 parts of Herba Agrimoniae, Herba Patriniae 20
～30 parts.
3. application according to claim 1, it is characterised in that described compound traditional Chinese medicine composite, its dosage form are decoction, sugar
Slurry agent, mixture, granule, tablet or capsule.
4. application according to claim 1, it is characterised in that described compound traditional Chinese medicine composite is prepared as follows
Arrive：By the Chinese crude drug Radix Astragali Preparata of formula ratio, Radix Codonopsis (parched), Rhizoma Atractylodis Macrocephalae (parched), Poria, Rhizoma Dioscoreae, Radix Glycyrrhizae Preparata, process Fructus Mume, Rhizoma Sparganii, Rhizoma Curcumae, celestial being
Crane grass and Herba Patriniae add water to cook and obtain final product.
5. application according to claim 4, it is characterised in that decoct every time, the weight of the water of addition is Chinese crude drug gross weight
5～20 times of amount；The number of times of decoction is 1～3 time, and each decocting time is 1～3 hour.
6. the application according to claim 4 or 5, it is characterised in that after adding water to cook, decocting liquid concentration is obtained final product.
7. application according to claim 6, it is characterised in that sucrose is added or be added without in concentrated solution, sterilizing is made
Into syrup or decoction；Or, dextrin, steviosin are added in concentrated solution, tablet, capsule or granule are made.
8. the application according to claim 1 or 7, it is characterised in that described compound traditional Chinese medicine composite passes through strengthening vital QI to eliminate pathogenic factors
So as to reduce the Lung metastases degree of melanoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710029836.8A CN106511915B (en) | 2017-01-16 | 2017-01-16 | A kind of compound traditional Chinese medicine composite is inhibiting the application in cutaneous melanoma Lung metastases drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710029836.8A CN106511915B (en) | 2017-01-16 | 2017-01-16 | A kind of compound traditional Chinese medicine composite is inhibiting the application in cutaneous melanoma Lung metastases drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106511915A true CN106511915A (en) | 2017-03-22 |
| CN106511915B CN106511915B (en) | 2019-06-21 |
Family
ID=58335481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710029836.8A Active CN106511915B (en) | 2017-01-16 | 2017-01-16 | A kind of compound traditional Chinese medicine composite is inhibiting the application in cutaneous melanoma Lung metastases drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106511915B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI701037B (en) * | 2019-06-18 | 2020-08-11 | 聖蓮生物科技股份有限公司 | An herbal composition for inhibiting melanoma cell metastasis and manufacturing method thereof |
| US20210205402A1 (en) * | 2019-06-18 | 2021-07-08 | St. Lotus Biotech Corp. | Herbal composition for inhibiting melanoma cell metastasis and manufacturing method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103494915A (en) * | 2013-09-30 | 2014-01-08 | 南京正亮医药科技有限公司 | Preparation method and application of breast lump dissipating tablet |
-
2017
- 2017-01-16 CN CN201710029836.8A patent/CN106511915B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103494915A (en) * | 2013-09-30 | 2014-01-08 | 南京正亮医药科技有限公司 | Preparation method and application of breast lump dissipating tablet |
Non-Patent Citations (2)
| Title |
|---|
| 杨振江等: "髓清丸对裸小鼠黑色素瘤B16自发性肺转移影响的研究", 《成都中医药大学学报》 * |
| 钱彦方等: "中医药预防恶性肿瘤复发和转移的研究进展(1)", 《河北中医药学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI701037B (en) * | 2019-06-18 | 2020-08-11 | 聖蓮生物科技股份有限公司 | An herbal composition for inhibiting melanoma cell metastasis and manufacturing method thereof |
| US20210205402A1 (en) * | 2019-06-18 | 2021-07-08 | St. Lotus Biotech Corp. | Herbal composition for inhibiting melanoma cell metastasis and manufacturing method thereof |
| US11622989B2 (en) * | 2019-06-18 | 2023-04-11 | St. Lotus Biotech Corp. | Method for inhibiting melanoma cell metastasis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106511915B (en) | 2019-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106390013B (en) | It is a kind of inhibit colorectal cancer hepatic metastases compound traditional Chinese medicine composite preparation method and application | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN105456897A (en) | Traditional Chinese medicine composition containing argy wormwood leaf for treating spleen deficiency gasterasthenia type chronic gastritis | |
| CN108567820A (en) | A kind of Chinese medicine composition and preparation method thereof for oncotherapy | |
| CN1167452C (en) | Medicine for treating AIDS | |
| CN101062221A (en) | Medicine for treating gastric ulcer and duodenal ulcer | |
| CN106511915A (en) | Applications of compound traditional Chinese medicinal composition in preparing medicines for inhibiting skin melanoma lung metastasis | |
| CN106075056A (en) | A kind of Ganoderma lucidum and preparation method improving immunity and improving gastrointestinal function | |
| CN105999096A (en) | Composition for enhancing immunity and application | |
| CN105435125A (en) | Chinese herbal medicine beneficial for upper gastrointestinal cancer postoperative rehabilitation | |
| CN112891485B (en) | Traditional Chinese medicine composition for treating neocoronary pneumonia | |
| CN104257883A (en) | Traditional Chinese medicine composition for treating leucopenia after chemotherapy | |
| CN101954034B (en) | Chinese medicinal preparation for treating acquired immune deficiency syndrome and preparation method thereof | |
| CN104225425A (en) | Chinese herbal preparation for enhancing immunity, improving sleep and preventing cardio-cerebrovascular disease, and preparation method thereof | |
| CN103041233A (en) | Pharmaceutical composition for treating infantile diarrhea and preparation method thereof | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN106421665B (en) | A kind of compound traditional Chinese medicine composite improves the immunity of the human body the application in drug in preparation | |
| CN104587300A (en) | Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition | |
| CN102100814A (en) | Method for preparing nanometer traditional Chinese medicine for treating severe asthma and production method thereof | |
| CN101829213B (en) | Medicine composition for treating asthma and preparation method thereof | |
| CN105748937A (en) | Traditional Chinese medicine composition for postoperative rehabilitation of differentiated thyroid carcinoma | |
| CN105250435A (en) | Compound Chinese herbal medicine preparation for treating influenza and preparation method of compound Chinese herbal medicine preparation | |
| CN104800573A (en) | Chinese medicinal composition for treating liver cancer and preparation method thereof | |
| CN104547695B (en) | It is a kind of for treating the pharmaceutical composition and its application of trigeminal neuralgia | |
| CN103721154A (en) | Traditional Chinese medicinal preparation for treating gastrointestinal diseases and preparation method of traditional Chinese medicinal preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |